Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01879748 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline
A Phase 1 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01879748: Completed Phase 1 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT01879748 is a Phase 1 study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 64 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01879748, a Phase 1 study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the pharmacokinetics of rasagiline in healthy Japanese and Caucasian subjects after single and multiple doses of rasagiline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rasagiline
Study Locations (1)
California
- Teva Investigational Site 10738 - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-06 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT01879748 record still lists
NCT01879748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01879748 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01879748 about?
NCT01879748 is a clinical study titled "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline". This study is designed to evaluate the pharmacokinetics of rasagiline in healthy Japanese and Caucasian subjects after single and multiple doses of rasagiline.
What is the current status of trial NCT01879748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2013-06. Estimated completion is 2013-11.
What conditions does trial NCT01879748 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT01879748?
The interventions under investigation include: Placebo (DRUG), Rasagiline (DRUG).
Who is sponsoring clinical trial NCT01879748?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01879748 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01879748's enrollment target sits among peer trials
64 72nd of 158 higher than 86 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia